• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy

    2022-06-29 01:46:56WanTingCaoRongHuangShanLiuYiHongFanMaoShengXuYiXuHuiNi
    World Journal of Gastroenterology 2022年23期

    Wan-Ting Cao,Rong Huang, Shan Liu,Yi-Hong Fan,Mao-Sheng Xu, Yi Xu,Hui Ni

    Abstract

    Key Words: Infliximab trough level; C-reactive protein; Fecal calprotectin; Crohn’s disease; Clinical remission; Long-term endoscopic outcomes

    INTRODUCTION

    Crohn’s disease (CD) is a persistently progressive disease with nonspecific inflammation characterized by disease scope involving the whole digestive tract and disease depth involving the whole intestinal wall. The accumulation damage of intestinal walls contributes to the occurrence of stenosis, fistula and even abscess, reducing the life quality. Therefore, recent clinical studies have consistently concluded that therapeutic strategies and targets play key roles in controlling CD progression. Setting different therapeutic targets will have different disease outcomes. Clinical response, focusing only on the improvement of clinical symptoms, can improve the quality of daily life but not affect long-term treatment outcomes. CD patients who do not achieve deep remission may be aggravated persistently,while achieving deep remission could reduce long-term hospitalization and surgery rates. Deep remission is mainly defined in previous studies as endoscopic remission or mucosal healing. Biologics,as an important step in the therapeutic strategy of CD, can effectively control the disease progression if conducted early and completely.

    In consideration of the wide use of infliximab (IFX), precisely predicting the long-term endoscopic outcomes is stressed by more and more inflammatory bowel disease (IBD) physicians. Although the IFX trough level (ITL) has been proven to be closely related to the outcome of CD, ITL alone may be biased in predicting the outcome of CD. Monitoring inflammation biomarkers is one of the important links of IFX therapy, including C-reaction protein (CRP), fecal calprotectin (FCP),etc.High inflammatory load affects the pharmacokinetics of IFX, inducing secondary nonresponse by decreasing blood drug concentration. Currently, it is believed that inflammatory biomarkers are good predictors of disease activity,but there is still a lack of reliable evidence for predicting disease remission. Therefore, this study intends to evaluate long-term endoscopic outcomes of CD patients receiving IFX treatment by combining the blood drug concentration and inflammatory biomarkers.

    MATERIALS AND METHODS

    Study subjects design

    A single-center retrospective research was implemented at the First Affiliated Hospital of Zhejiang Chinese Medical University. CD patients under IFX therapy from January 2012 to December 2020 were collected. One hundred and eighty-one CD patients underwent IFX treatment. One hundred and fiftyone CD patients underwent endoscopy as well as serum concentration monitoring at week 14 after the third dose of IFX induction therapy. Inclusion criteria: (1) Endoscopic remission at week 14 [Crohn’s disease endoscopic index of severity (CDEIS) score ≤ 2 points or Rutgeerts ≤ i1]; (2) Clinical remission after IFX induction therapy without corticosteroids more than 6 mo; and (3) Therapeutic strategy during maintenance stage was designed as IFX 5 mg/kg every 8 wk combined with azathioprine (AZA) 50 mg every day. Therapeutic strategic was modulated if CD patients were confronted with clinical relapse or secondary loss of response (LOR), and data analysis focused on the treatment course when patients received IFX 5 mg/kg and AZA therapy regularly. Secondary LOR was defined as a recurrence of the disease during IFX maintenance therapy. Two criteria were met to determine LOR: The recurrence of symptoms of IBD in clinical remission after induction therapy and symptoms caused by the inflammatory activity of IBD itself. Clinical relapse means Crohn’s disease activity index > 150 points. Blood drug concentration monitoring and clinical, laboratory, endoscopic and imaging evaluation were implemented every 2 mo since the third dose of IFX induction therapy in all patients. The study was divided into two stages, step I study period defined as IFX maintenance therapy during week 14 to week 54 and step II study period defined as IFX maintenance therapy during week 54 to week 108.

    Data collection

    General data included age, sex, course, disease location, disease behavior, medication history and history of intestinal surgery. Laboratory indicators include white blood cell count, blood platelet count,CRP, erythrocyte sedimentation rate, serum albumin, FCP, ITL and anti-IFX antibody. Evaluation indicators of disease severity included Crohn’s disease activity index score on clinical severity, CDEIS score on endoscopic severity in CD patients without intestinal surgery and Rutgeerts score on endoscopic severity in CD patients with intestinal surgery.

    Outcome definition

    Endoscopic outcomes at week 54 and week 108 after IFX initial therapy were evaluated by specialist physicians on IBD under electronic colonoscopy. Endoscopic remission was defined as CDEIS score ≤ 2 or Rutgeerts score ≤ i1, and endoscopic activity was defined as CDEIS score > 2 or Rutgeerts score > i1.Survival outcomes during IFX maintenance therapy were concentrated on endoscopic relapse-free survival, defined as sustained endoscopic remission during step I study period or step II study period.

    Statistical analysis

    Descriptive statistical analysis was used to describe characteristics of CD patients. Number of cases(percentage) was used to describe categorial variable. mean ± SD was used to describe continuous variable. Nonparametric Mann-Whitney test was used to compare two groups in enumeration data or measurement data without normal distribution. Two-sample t test was used to compare two groups in measurement data with normal distribution. One-way analysis of variance was used to compare multigroup if data satisfied homogeneity of variance. Nonparametric Kruskal-Wallis test was used to compare multi-group if data not satisfied homogeneity of variance. SPSS 23.0 (Armonk, NY, United States) was used to analyze differences between groups. APvalue < 0.05 was considered significant.

    Receiver-operating characteristic (ROC) analysis was used to identify the best cut off level of ITL on predicting endoscopic remission as well as sensitivity, specificity, positive predictive value, negative predictive value, area under the curve and Youden Index. Univariate logistic regression analysis was used to identify the association between endoscopic activity and predictors. Log-rank test was used to identify the association between endoscopic relapse and predictors. GraphPad Prism9.0 (San Diego, CA,United States) was used to draw histograms and survival analysis curves and implement log-rank test.MedCalc19.0 was used to draw ROC curve and analyze the predictive value of indicators on endoscopic outcomes. APvalue < 0.05 was considered significant.

    RESULTS

    Characteristics of study subjects

    In total, the study cohort collected 112 CD patients achieving clinical remission after IFX induction therapy. In step I study, 19 CD patients were excluded due to data absence (n= 1, 5.26%) and endoscopic activity at week 14 (n= 18, 94.74%), while 93 CD patients with endoscopic remission at week 14 were included. In step II study, 58 CD patients were excluded due to course of therapy shorter than 2 years (n= 10, 17.24%), secondary non-response of IFX (n= 12, 20.69%), suspension of IFX therapy within 2 years for disease remission (n= 10, 17.24%) and endoscopic activity at week 54 (n= 26, 44.83%), while 54 CD patients with endoscopic remission at week 54 were included. These 12 patients did not satisfy indications of operation and received hormonotherapy as the primary choice to alleviate disease, for our center lacked other biological agents at that time. All CD patients under IFX maintenance therapy were combined with AZA (Figure 1). The dose of IFX was 5 mg/kg every 8 wk, and the dose of AZA was 50 mg every day. Characteristics of CD patients included in study are shown in Table 1.

    Correlation between ITL, inflammatory biomarkers and endoscopic outcomes

    In step I study, 67/93 CD patients (72.04%) sustained endoscopic remission at week 54 among.Multivariable regression analysis revealed that only ITL (OR = 0.666, 95%CI: 0.514-0.862,P= 0.002) and FCP (OR = 1.002, 95%CI: 1.001-1.004,P= 0.002) were independent risk of endoscopic activity at week 54(Table 2). Based on incremental gain analysis, an ITL range of 5.0-7.4 μg/mL was correlated with sustained endoscopic remission rate of more than 85% (Figure 2).

    In step II study, 42/54 CD patients (77.78%) sustained endoscopic remission at week 108.Multivariable regression analysis revealed that only ITL (OR = 0.466, 95%CI: 0.247-0.877,P= 0.018) and CRP (OR = 1.590, 95%CI: 1.007-2.510,P= 0.047) were independent risks of endoscopic activity at week 108 (Table 2). Based on incremental gain analysis, an ITL range of 2.0-3.9 μg/mL was correlated with sustained endoscopic remission rate of more than 85% (Figure 2).

    Predictive value of ITL and inflammatory biomarkers on endoscopic outcomes

    In step I study, the ROC analysis demonstrated that the best cut off level of ITL and FCP at week 14 on predicting endoscopic relapse at week 54 was 5.60 μg/ml (AUC = 0.83, 95%CI: 0.73-0.90, P < 0.001) and 238 μg/g (AUC = 0.82, 95%CI: 0.72-0.89, P < 0.001) (Table 3 and Figure 3). CD patients with ITL ≤ 5.60 μg/ml and FCP > 238 μg/g at week 14 had 82% probability of endoscopic relapse at week 54. However,CD patients with ITL > 5.60 μg/ml and FCP ≤ 238 μg/g at week 14 had 98% probability of sustained endoscopic remission at week 54.

    In step II study, the ROC analysis demonstrated that the best cut off level of ITL and CRP at week 54 on predicting endoscopic relapse at week 108 was 2.10 μg/mL (AUC = 0.85, 95%CI: 0.72-0.93,P< 0.001)and 3.00 mg/L (AUC = 0.73, 95%CI: 0.60-0.84,P= 0.012) (Table 3 and Figure 3). CD patients with ITL ≤2.10 μg/mL and CRP > 3.00 mg/L at week 54 had 100% probability of endoscopic relapse at week 108.However, CD patients with ITL > 2.10 μg/mL and CRP ≤ 3.00 mg/L at week 54 had 97% probability of sustained endoscopic remission at week 108.

    Correlation between ITL, inflammatory biomarkers and endoscopic relapse-free survival

    In step I study, 26/93 (27.96%) CD patients had experienced endoscopic relapse from week 14 to week 54 of IFX maintenance therapy. The estimated endoscopic relapse-free rate was 46/48 (95.83%) in CD patients with ITL > 5.6 μg/ml and 21/45 (46.67%) in CD patients with ITL ≤ 5.6 μg/ml. The median time to endoscopic relapse of CD patients with ITL ≤ 5.6 μg/ml was 32.00 wk shorter than those with ITL >5.6 μg/ml [hazard ratio (HR) = 16.19, 95%CI: 7.44-35.22, P < 0.0001] (Figure 4A). The estimated endoscopic relapse-free rate was 6/25 (24.00%) in CD patients with FCP > 238 μg/g and 61/68 (89.71%)in CD patients with FCP ≤ 238 μg/g. The median time to endoscopic relapse of CD patients with FCP >238 μg/g was 21.00 wk shorter than those with FCP ≤ 238 μg/g (HR = 11.25, 95%CI: 4.26-29.73, P <0.0001) (Figure 4B).

    Table 1 Clinical characteristics of Crohn‘s disease patients with endoscopic remission

    In step II study, 12/54 (22.22%) CD patients had experienced endoscopic relapse from week 54 to week 108 of IFX maintenance therapy. The estimated endoscopic relapse-free rate was 38/41 (92.68%) in CD patients with ITL > 2.1 μg/mL and 4/13 (30.77%) in CD patients with ITL ≤ 2.1 μg/mL. The median time to endoscopic relapse of CD patients with ITL ≤ 2.1 μg/mL was 40.00 w, shorter than those with ITL > 2.1 μg/mL (HR = 13.14, 95%CI: 3.07-56.27,P< 0.0001) (Figure 4D). The estimated endoscopic relapse-free rate was 4/8 (50.00%) in CD patients with CRP > 3.00 mg/L and 40/46 (86.96%) in CD patients with CRP ≤ 3.00 mg/L. The median time to endoscopic relapse of CD patients with CRP > 3.00 mg/L was 50.00 wk shorter than those with CRP ≤ 3.00 mg/L (HR = 7.85, 95%CI: 1.31-46.85,P< 0.0001)(Figure 4C).

    DISCUSSION

    Several studies have confirmed that different ITLs brought about different outcomes of CD under IFX therapy (Table 4). Tanget al[1] discovered that CD patients achieving mucosal healing at week 14 of IFXtherapy with ITL > 2.5 μg/mL at week 14 had 71% chance of mucosal healing at week 54, while patients with ITL < 2.5 μg/mL had only 33% chance. ITL ≥ 3 μg/mL at the beginning of IFX maintenance therapy was confirmed as a predictor of sustained response to IFX in CD patients[2]. Recently a prospective study in Japan verified that CD patients with ITL ≥ 3 μg/mL at week 14 after IFX initial therapy had much better long-term clinical outcomes than patients with ITL < 3 μg/mL, of which survival analysis indicated 100% probability of clinical remission at week 108 in the former and 33.3%probability in the latter[3]. A meta-analysis determined that ITL > 2.0 μg/mL of IBD patients under IFX maintenance therapy contributes to better prognosis such as clinical remission or mucosal healing[4].Similarly, this study found that CD patients with ITL > 5.6 μg/mL at week 14 had a large chance ofachieving sustained endoscopic remission during IFX maintenance therapy as well as CD patients with ITL > 2.1 μg/mL at week 54. Borrenet al[5] implemented a multi-center retrospective study and concluded that low ITL in IBD patients during IFX maintenance therapy could not be a good predictor of clinical relapse in the next 2 years, suggesting that proactive therapeutic drug monitoring was not suitable in this group. However, this study discovered that CD patients with ITL ≤ 5.6 μg/mL at week 14 or ITL ≤ 2.1 μg/mL at week 54 were more likely to experience endoscopic relapse during the 1-year follow-up period.

    Table 2 Predictive indicators of endoscopic relapse in Crohn's disease patients with endoscopic remission

    Table 3 Predictive value of indicators on endoscopic relapse

    Figure 1 Patients selected and outcome of infliximab therapy. CD: Crohn‘s disease; EA: Endoscopic activity; IFX: Infliximab.

    Table 4 Previous research of infliximab trough level on deep remission in inflammatory bowel disease

    Figure 2 Incremental gain analysis of sustained endoscopic remission rate in relation to infliximab trough level at week 14 and week 54.

    According to previous studies, the challenge for IBD physicians is to frame the more suitable blood trough level of IFX to achieve better disease prognosis in clinical therapy. The elements associated with the blood trough level of IFX can be classified into three areas. Above all, the better the therapeutic goal desired by IBD physicians or patients, the higher the blood trough level of IFX is required. An observational study contraposing to CD patients with a history of intestinal surgery by Imaedaet al[6] verified that mucosal healing required higher ITLs as more than 4.0 μg/mL compared to those to achieve normalization of routine clinical markers. Papamichaelet al[7] considered that ITL surpassing 9.7 μg/mL indicated 80% probability of endoscopic remission in CD patients under IFX maintenance therapy, while ITL surpassing 2.2 μg/mL was associated only with biochemical remission. Recently, a prospective study verified that ITL > 8.0 μg/mL was highly correlated with histological emission and sustained histological remission in IBD patients[8]. Perianal fistula, the most universal complications of CD patients, is another therapeutic goal. A retrospective cross-sectional study by Plevriset al[9]manifested that perianal fistula healing or closure is associated with higher ITLs as more than 7.1 μg/mL.

    Secondly, each clinical study had different stages of IFX drug monitoring, especially during maintenance therapy. ITL continues to decrease as time passed during IFX maintenance therapy[10]. A cross-sectional study of IBD patients under IFX therapy with a fixed dose more than 6 mo found that IBD patients with ITL ≥ 3.4 μg/mL had a 73% chance of endoscopic mucosal healing[11]. Kanget al[12]showed that ITL ≥ 5 μg/mL during IFX maintenance therapy could identify mucosal healing in pediatric CD patients with 80% specificity. Fenget al[13] innovatively integrated ITL levels in different time stages to identify endoscopic mucosal healing in CD patients, indicating that patients with ITL >4.85 μg/mL at week 14 and ITL > 2.85 μg/mL at week 30 had an 80% chance of achieving endoscopic mucosal healing. Based on incremental gain analysis in our study, sustained endoscopic remission rate at week 54 reached only 54.63% at an ITL range of 2.5 to 4.9 μg/mL at week 14 while corresponding numbers at week 108 was 89.47% at an ITL range of 2.0 to 3.9 μg/mL at week 54. Therefore, the study held the view that CD patients with endoscopic remission need higher ITL at the beginning of IFX maintenance therapy (≥ 5.6 μg/mL at week 14) than after IFX maintenance therapy over a half year (≥2.1 μg/mL at week 54). In addition, CD patients achieving endoscopic remission after IFX induction therapy and sustained endoscopic remission more than a half year may not need high ITL to maintain endoscopic remission.

    Figure 3 Receiver operator characteristic curve of infliximab trough level and inflammatory biomarkers in predicting endoscopic outcomes. A: Receiver operator characteristic (ROC) curve of infliximab trough level at week 14 in predicting endoscopic remission of Crohn’s disease (CD) at week 54; B: ROC curve of fecal calprotectin at week 14 in predicting endoscopic remission of CD at week 54; C: ROC curve of infliximab trough level at week 54 in predicting endoscopic remission of CD at week 108; D: ROC of C-reactive protein at week 54 in predicting endoscopic remission of CD at week 108. ITL: Infliximab trough level; CRP: C-reactive protein; FCP: Fecal calprotectin; AUC: Area under the curve.

    The third element is therapeutic optimization of IFX in IBD. Adverse IFX response as high ATI level or low ITL may occur in a few CD patients during IFX maintenance therapy. Several clinical studies held the view that severe inflammatory activity of CD patients could change pharmacokinetics of antitumor necrosis factor α biology[14-16]. Therapeutic optimization as increasing fixed dose from 5 mg/kg to 10 mg/kg or shortening injection interval form every 8 wk to 4-6 wk contributes to increase ITL and decrease ATI level. A study from Greece demonstrated that, for the initial measurement after therapeutic adjustment, ITL increased from 1.47 μg/mL to 8.50 μg/mL in patients with therapeutic optimization while ITL decreased from 5.65 μg/mL to 3.8μg/ml in patients without therapeutic optimization[10]. A multi-center randomized clinical trial conducted by Dreesenet al[17] showed that CD patients under IFX maintenance therapy as 5 mg/kg had high probability of no mucosal ulcer under endoscopy at week 54 with ITL more than 7.3mg/L, and CD patients under intensified dose IFX therapy as 10 mg/kg had 94% probability of no mucosal ulcer under endoscopy with ITL rising to more than 10.6 mg/L. Therefore, intensified therapy may contribute to mucosal healing in CD patients with ulceration if IFX injection dose is less than 10 mg/kg and ITL is less than 10.6 μg/mL. However, a few CD patients will accept combination therapy of IFX and immunosuppressant to boost the efficacy,especially AZA and mercaptopurine. AZA is a precursor of mercaptopurine, and two components ultimately produce thioguanine to exert clinical effect during metabolism. A study verified that thioguanine concentration more than 125 pmol/8 × 108red blood cells could enhance ITL to 8.3 μg/mL or more and decrease positive rate of ATI[18,19]. Hence, this study mainly included CD patients with sustained clinical remission more than 6 mo under fixed therapeutic strategy of IFX 5 mg/kg every 8 wk combined with AZA 50 mg every day. Retrospective records of CD patients included would suspend if therapy strategy changed, such as intensive therapy of IFX, conversion therapy of other biologics and combination therapy of surgery or other medications. The study design eliminated the influence of therapeutic adjustment on ITL.

    Figure 4 Proportion without endoscopic relapse. A. Time since infliximab (IFX) therapy at week 14 [IFX trough level (ITL) > 5.6 μg/mL vs ITL ≤ 5.6 μg/mL];B: Time to IFX therapy at week 14 (fecal calprotectin ≤ 238 μg/g vs fecal calprotectin > 238 μg/g]; C: Time to IFX therapy at week 54 (C-reactive protein ≤ 3.0mg/L vs C-reactive protein > 3.0 mg/L); D: Time to IFX therapy at week 54 (ITL > 2.1 μg/mL vs ITL ≤ 2.1 μg/mL). ITL: Infliximab trough level; CRP: C-reactive protein; FCP:Fecal calprotectin; IFX: Infliximab.

    The greatest strength of inflammatory biomarkers compared with blood trough level is that they are unaffected by time during different monitoring stages of biological therapy in IBD patients. This study showed that ITL > 5.6 μg/mL combined with FCP ≤ 238 μg/g at week 14 moderately predicted sustained endoscopic remission during the 1-year follow-up period on CD patients with positive predictive value more than 95% as well as ITL > 2.1 μg/mL combined with CRP ≤ 3.00 mg/L at week 54, superior to use ITL as the only predictor. FCP and CRP are considered as the most universal and typical biomarkers of inflammatory evaluation in IBD, also verified to be the independent risk factors of adverse endoscopic outcomes. The study confirmed that combining blood trough level with inflammatory biomarkers contributed to improving the accuracy of the prediction on endoscopic outcomes. A post hoc analysis from the CALM study manifested that CD patients with FCP < 250 μg/g mostly achieved CDEIS < 4 without deep ulceration, regardless of whether CRP < 5 mg/L. However, among patients with CRP < 5 mg/L but FCP ≥ 250 μg/g, only 16.7% achieved CDEIS < 4 without deep ulceration[20]. The result indicated that the correlation between FCP normalization and endoscopic mucosal healing in CD patients was stronger than that of CRP normalization. A previous study verified that FCP is suitable for distinguishing mild endoscopic activity from endoscopic remission, while it is difficult to distinguish partial endoscopic remission from complete endoscopic remission[21]. Similar to blood trough level, the optimal cut off value of FCP for distinguishing endoscopic activity from endoscopic remission ranges from 71 μg/g to 250 μg/g with moderate diagnostic performance[22-27].The study identified that FCP > 276 μg/g predicted endoscopic activity at week 54 of CD patients with clinical remission at week 14 moderately with 84.6% sensitivity and 92.1% specificity. Unlike FCP, the sensitivity of CRP to mild intestinal inflammation was low and the level of CRP increased much more dramatically in CD patients with moderate to severe inflammation. Therefore, the previous study preferred to utilize CRP to distinguish moderate to severe endoscopic activity from mild to moderate endoscopic activity rather than distinguish mild endoscopic activity from endoscopic remission. A Spanish study showed that FCP > 155 μg/g in combination with CRP > 6.7 mg/L could identify endoscopic activity with 82% specificity[27].

    However, the study has shortcomings in some areas. Firstly, the retrospective single-center study with small sample, inferior to prospective multi-center with greater sample, comprised some confounding factors. More real-world studies and randomized controlled trials on guidance significance of ITL to therapeutic outcomes in IBD need to be conducted. Secondly, the study primarily concentrated on mucosal inflammation located in large intestine, ignoring small intestine due to the high cost and the incomplete scoring system of small intestinal evaluation accompanied by the poor compliance of patients and the laborious operation of endoscopists. Correlation between ITL and various small intestinal examinations including endoscopy or imageology may be the focus of the future study. Last but not least, definition of deep remission on CD has been tightened. Considering transmural inflammation of CD, endoscopy is confined to mucosal inflammation and macroscopical evaluation while imageology can accurately evaluate complete volume of intestinal wall and histopathological examination, which contributes to microscopical examination. Notwithstanding endoscopic remission considered as the main targets and histological remission considered as a novel target, the new concept of ‘disease clearance’, which includes clinical, endoscopic and microscopic remission, has drawn more and more attention from IBD physicians and may bring about a new upsurge of studies on IFX monitoring and new therapeutic targets[28].

    CONCLUSION

    In conclusion, during IFX maintenance treatment, low ITL, high CRP level and high FCP level were independent risk factors of long-term adverse endoscopy outcomes in CD patients with clinical remission. Combination of ITL, CRP and FCP contribute to long-term endoscopic prognosis monitoring.The best cut off values of ITL for predicting endoscopic activity within 1-year follow up were 5.60 μg/mL at week 14 and 2.10 μg/mL at week 54. In addition, ITL ≤ 5.60 μg/mL in combination with FCP> 238 μg/g at week 14 as well as ITL ≤ 2.10 μg/mL in combination with CRP > 3.00 mg/L at week 54 increased the precision of prediction on endoscopic outcomes at week 54 and week 108, respectively.Therapeutic optimization is still recommended in CD patients achieving endoscopic remission,provided that low ITLs or high levels of inflammatory biomarkers, such as CRP or FCP, arise to prevent endoscopic recurrence as soon as possible.

    ARTICLE HIGHLIGHTS

    Research conclusions

    The best cut off values of ITL for predicting endoscopic activity within 1-year follow up was 5.60 μg/mL at week 14 and 2.10 μg/mL at week 54. In addition, ITL ≤ 5.60 μg/mL in combination with FCP > 238 μg/g at week 14 as well as ITL ≤ 2.10 μg/mL in combination with CRP > 3.00 mg/L at week 54 increased the precision of prediction on endoscopic outcomes at week 54 and week 108, respectively.

    Research perspectives

    In view of the fact that conduction of intensive monitoring for biological management plays a vital role in precise treatment for CD patients, much larger and more stringent prospective studies are warranted to provide the best predictive models as acknowledged globally in allusion to long-term endoscopic outcomes of CD patients under IFX therapy.

    ACKNOWLEDGEMENTS

    The authors would like to thank Dr. Bin Lv, Full Professor and Chief Physician at the First Affiliated Hospital of Zhejiang Chinese Medical University, Department of Gastroenterology, for his help in revising this paper, and Shan Liu, at the First Affiliated Hospital of Zhejiang Chinese Medical University, Clinical Evaluation Center, for help with statistical analysis.

    FOOTNOTES

    Author contributions:Fan YH designed the research; Cao WT performed the research; Cao WT and Liu S analyzed the data; Cao WT, Huang R, Ni H and Xu MS wrote the paper; Xu Y supervised the paper; All authors have read and approve the final manuscript.

    Supported byNational Natural Science Foundation of China, No. 81473506 and No. 81971600; Zhejiang TCM Science and Technology Project, No. 2019ZA056, No. 2021ZA057 and No. 2016ZA077.

    Institutional review board statement:This study was reviewed and approved by the ethics committee of the First Affiliated Hospital of Zhejiang Chinese Medical University, No. 2021-KL-024-02.

    Informed consent statement:All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

    Conflict-of-interest statement:The authors declare that they have no conflict of interest.

    Data sharing statement:Some or all data, models, or code generated or used during the study are available from the corresponding author by request. People could contact the corresponding author to get the data which is not used for commercial purposes.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:China

    ORCID number:Wan-Ting Cao 0000-0001-7277-4492; Rong Huang 0000-0002-8360-7777; Shan Liu 0000-0001-9139-3257;Yi-Hong Fan 0000-0001-8217-9793; Mao Sheng Xu 0000-0002-2396-1600; Yi Xu 0000-0002-3265-9534; Hui Ni 0000-0001-8973-8834.

    S-Editor:Ma YJ

    L-Editor:Filipodia

    P-Editor:Cai YX

    av天堂中文字幕网| 国产一区二区在线av高清观看| 99热只有精品国产| 国产精品一区二区三区四区久久| 一级毛片我不卡| 校园春色视频在线观看| 免费av观看视频| 悠悠久久av| 国产精品,欧美在线| а√天堂www在线а√下载| 乱系列少妇在线播放| 国产综合懂色| 在线观看免费视频日本深夜| 成人三级黄色视频| 中国国产av一级| 成人无遮挡网站| 人妻久久中文字幕网| 免费一级毛片在线播放高清视频| 国产精品一区二区性色av| 色在线成人网| 我要看日韩黄色一级片| 国产精华一区二区三区| 老司机福利观看| 亚洲中文日韩欧美视频| 午夜福利在线在线| 免费观看人在逋| 99热全是精品| 国产成人一区二区在线| 一级a爱片免费观看的视频| 听说在线观看完整版免费高清| 熟女人妻精品中文字幕| 在线国产一区二区在线| 国产男靠女视频免费网站| 少妇的逼好多水| 男插女下体视频免费在线播放| 亚洲美女搞黄在线观看 | 变态另类丝袜制服| 免费电影在线观看免费观看| 少妇丰满av| 91av网一区二区| 久久99热这里只有精品18| 长腿黑丝高跟| 一区二区三区四区激情视频 | 一个人观看的视频www高清免费观看| 99久久无色码亚洲精品果冻| 午夜福利视频1000在线观看| 非洲黑人性xxxx精品又粗又长| 久久草成人影院| 99久久成人亚洲精品观看| 伦理电影大哥的女人| 精品人妻视频免费看| 综合色av麻豆| aaaaa片日本免费| 麻豆一二三区av精品| 成人av一区二区三区在线看| 噜噜噜噜噜久久久久久91| 51国产日韩欧美| 性欧美人与动物交配| 成人二区视频| 色视频www国产| 99热全是精品| 成年av动漫网址| 真实男女啪啪啪动态图| 亚洲成av人片在线播放无| 看免费成人av毛片| 永久网站在线| 蜜臀久久99精品久久宅男| 九九久久精品国产亚洲av麻豆| 国产精品日韩av在线免费观看| 日韩av在线大香蕉| 国产美女午夜福利| 尤物成人国产欧美一区二区三区| 18+在线观看网站| av专区在线播放| 久久久久久久久中文| .国产精品久久| 久久精品国产亚洲av香蕉五月| 午夜亚洲福利在线播放| 夜夜爽天天搞| 99九九线精品视频在线观看视频| 亚洲熟妇中文字幕五十中出| 久久午夜福利片| 老司机福利观看| 黄色一级大片看看| av免费在线看不卡| 免费观看的影片在线观看| 亚洲在线自拍视频| 此物有八面人人有两片| 99国产精品一区二区蜜桃av| 男女那种视频在线观看| 国产爱豆传媒在线观看| 亚洲av一区综合| 最近的中文字幕免费完整| 99热这里只有是精品在线观看| 中文字幕免费在线视频6| 中文字幕久久专区| 2021天堂中文幕一二区在线观| 在线观看美女被高潮喷水网站| 久久精品国产99精品国产亚洲性色| 又爽又黄a免费视频| 久久久精品大字幕| 亚洲性久久影院| 久久精品91蜜桃| 亚洲精品一区av在线观看| 久久精品人妻少妇| 亚洲激情五月婷婷啪啪| 色噜噜av男人的天堂激情| 99九九线精品视频在线观看视频| 人妻少妇偷人精品九色| 精品日产1卡2卡| 看片在线看免费视频| 夜夜看夜夜爽夜夜摸| 中文字幕av成人在线电影| 色综合亚洲欧美另类图片| 精品免费久久久久久久清纯| av女优亚洲男人天堂| 亚洲天堂国产精品一区在线| 日韩欧美在线乱码| 黄色一级大片看看| 亚洲国产高清在线一区二区三| 色在线成人网| 日韩中字成人| 一级毛片电影观看 | 午夜视频国产福利| 亚洲成人av在线免费| 午夜福利18| 国产国拍精品亚洲av在线观看| 男女视频在线观看网站免费| 老司机午夜福利在线观看视频| 亚洲最大成人中文| 我的女老师完整版在线观看| 久99久视频精品免费| 日韩成人伦理影院| 最新中文字幕久久久久| 亚洲av一区综合| 人妻少妇偷人精品九色| 成人美女网站在线观看视频| 国产精品无大码| 69人妻影院| 亚洲久久久久久中文字幕| 国产黄片美女视频| 亚洲av.av天堂| 成人av在线播放网站| 日韩在线高清观看一区二区三区| 国产成人91sexporn| 麻豆国产av国片精品| 亚洲精华国产精华液的使用体验 | 欧美日韩乱码在线| 免费观看精品视频网站| 国产三级中文精品| 亚洲综合色惰| 免费高清视频大片| 久久天躁狠狠躁夜夜2o2o| 久久精品国产亚洲av天美| 一个人看视频在线观看www免费| 国产一级毛片七仙女欲春2| 亚洲自偷自拍三级| 欧美色欧美亚洲另类二区| 亚洲av五月六月丁香网| 女生性感内裤真人,穿戴方法视频| 成年免费大片在线观看| 精品熟女少妇av免费看| 久久久精品欧美日韩精品| 一卡2卡三卡四卡精品乱码亚洲| 99视频精品全部免费 在线| 99在线人妻在线中文字幕| 亚洲成a人片在线一区二区| 黄色日韩在线| 亚洲熟妇熟女久久| 欧美极品一区二区三区四区| 老熟妇仑乱视频hdxx| 亚洲综合色惰| 日韩高清综合在线| 乱码一卡2卡4卡精品| 国产伦一二天堂av在线观看| 免费电影在线观看免费观看| 美女高潮的动态| av天堂中文字幕网| 在线观看美女被高潮喷水网站| 天堂影院成人在线观看| 亚洲美女黄片视频| 一级毛片我不卡| 成人一区二区视频在线观看| 亚洲欧美成人综合另类久久久 | 狠狠狠狠99中文字幕| 老女人水多毛片| 嫩草影视91久久| 日日摸夜夜添夜夜爱| 国产成人a区在线观看| 99国产极品粉嫩在线观看| 99久久无色码亚洲精品果冻| 国产亚洲精品综合一区在线观看| 亚洲av美国av| 日本黄色片子视频| 国产黄片美女视频| 国产一区二区亚洲精品在线观看| 精品人妻一区二区三区麻豆 | 日本欧美国产在线视频| 欧美激情久久久久久爽电影| 丰满乱子伦码专区| 国产高清三级在线| eeuss影院久久| 给我免费播放毛片高清在线观看| 老熟妇乱子伦视频在线观看| 深爱激情五月婷婷| 成人欧美大片| av免费在线看不卡| 特大巨黑吊av在线直播| 99久久久亚洲精品蜜臀av| 嫩草影院新地址| 中文字幕人妻熟人妻熟丝袜美| 此物有八面人人有两片| 国产精品嫩草影院av在线观看| 色5月婷婷丁香| 菩萨蛮人人尽说江南好唐韦庄 | 久久久久久久午夜电影| 国产aⅴ精品一区二区三区波| 亚洲乱码一区二区免费版| 日韩高清综合在线| 91狼人影院| 亚洲一级一片aⅴ在线观看| 亚洲一区高清亚洲精品| 国产高清视频在线播放一区| 亚洲七黄色美女视频| 欧美最黄视频在线播放免费| 免费av毛片视频| 秋霞在线观看毛片| 亚洲中文字幕日韩| 69av精品久久久久久| 青春草视频在线免费观看| eeuss影院久久| 熟女人妻精品中文字幕| 三级男女做爰猛烈吃奶摸视频| 欧美性猛交黑人性爽| 精品人妻一区二区三区麻豆 | 国产亚洲av嫩草精品影院| 色5月婷婷丁香| 国产一区亚洲一区在线观看| 99久久成人亚洲精品观看| 久久人人精品亚洲av| 日本欧美国产在线视频| 成人亚洲欧美一区二区av| av在线天堂中文字幕| 精品久久久久久久久久免费视频| 看非洲黑人一级黄片| 欧美xxxx性猛交bbbb| 在线a可以看的网站| 一级毛片久久久久久久久女| 亚洲av中文字字幕乱码综合| 免费高清视频大片| 国产精品永久免费网站| 看非洲黑人一级黄片| 国产黄色视频一区二区在线观看 | 特级一级黄色大片| 91久久精品国产一区二区三区| 精品人妻一区二区三区麻豆 | 午夜免费激情av| 人妻丰满熟妇av一区二区三区| 国产女主播在线喷水免费视频网站 | 国内少妇人妻偷人精品xxx网站| 精品久久久久久久久av| 欧洲精品卡2卡3卡4卡5卡区| 日韩中字成人| 国产精品伦人一区二区| 国产午夜福利久久久久久| 免费看美女性在线毛片视频| 99精品在免费线老司机午夜| av免费在线看不卡| 国内久久婷婷六月综合欲色啪| 人人妻人人澡欧美一区二区| 一级黄片播放器| 全区人妻精品视频| 天天躁日日操中文字幕| 又黄又爽又免费观看的视频| 淫秽高清视频在线观看| 国产av麻豆久久久久久久| 看非洲黑人一级黄片| 99热全是精品| 一进一出抽搐gif免费好疼| 性插视频无遮挡在线免费观看| av在线亚洲专区| 精品久久久久久久久av| 免费观看精品视频网站| 久久中文看片网| 女的被弄到高潮叫床怎么办| 村上凉子中文字幕在线| 久99久视频精品免费| 在线a可以看的网站| 91在线精品国自产拍蜜月| 人人妻人人看人人澡| 亚洲av美国av| 亚洲精品乱码久久久v下载方式| 午夜影院日韩av| 国产成人aa在线观看| 成人特级黄色片久久久久久久| 亚洲国产精品成人综合色| 国产亚洲精品av在线| 亚洲自偷自拍三级| 亚洲人成网站高清观看| 亚洲av美国av| 99热这里只有是精品50| 我的女老师完整版在线观看| 亚洲图色成人| 日本 av在线| 欧美中文日本在线观看视频| 日产精品乱码卡一卡2卡三| 亚洲国产色片| 1000部很黄的大片| 男人和女人高潮做爰伦理| 亚洲经典国产精华液单| 一个人观看的视频www高清免费观看| 国产成人一区二区在线| 亚洲av一区综合| 看片在线看免费视频| 99热只有精品国产| 亚洲图色成人| 国产高清激情床上av| 国产亚洲欧美98| 精品人妻偷拍中文字幕| 老司机影院成人| 国产黄片美女视频| 日本爱情动作片www.在线观看 | 亚洲欧美日韩卡通动漫| 日本熟妇午夜| 一级毛片久久久久久久久女| 国产免费男女视频| а√天堂www在线а√下载| 国产午夜精品论理片| 97在线视频观看| 精品久久久噜噜| 国产精品一及| 99热这里只有是精品50| 免费高清视频大片| 欧美潮喷喷水| 国国产精品蜜臀av免费| 99久久成人亚洲精品观看| 亚洲真实伦在线观看| 免费观看的影片在线观看| 尾随美女入室| eeuss影院久久| 亚洲欧美清纯卡通| 日韩在线高清观看一区二区三区| 在线观看一区二区三区| 99riav亚洲国产免费| 少妇的逼水好多| 少妇被粗大猛烈的视频| 亚洲最大成人手机在线| 欧美人与善性xxx| 精品午夜福利在线看| 欧美丝袜亚洲另类| 久久久久国产精品人妻aⅴ院| 亚洲精品色激情综合| 成人二区视频| 国产精品一区二区性色av| 亚洲av第一区精品v没综合| 天堂网av新在线| 亚洲国产精品sss在线观看| 久久午夜亚洲精品久久| 白带黄色成豆腐渣| 一个人观看的视频www高清免费观看| 日韩精品中文字幕看吧| 男女视频在线观看网站免费| 黄色日韩在线| 亚洲欧美清纯卡通| 我的老师免费观看完整版| 99久国产av精品国产电影| 在线天堂最新版资源| 久久午夜福利片| 在线a可以看的网站| 欧美成人一区二区免费高清观看| 国产老妇女一区| 一级毛片我不卡| 高清午夜精品一区二区三区 | 日本在线视频免费播放| 色综合亚洲欧美另类图片| 又爽又黄a免费视频| 免费av毛片视频| 国产av一区在线观看免费| 国产成人91sexporn| 尤物成人国产欧美一区二区三区| 亚洲av美国av| 日韩一区二区视频免费看| 国国产精品蜜臀av免费| 中国美白少妇内射xxxbb| 成人漫画全彩无遮挡| 亚洲欧美成人精品一区二区| 校园人妻丝袜中文字幕| 老熟妇乱子伦视频在线观看| 卡戴珊不雅视频在线播放| 网址你懂的国产日韩在线| 性插视频无遮挡在线免费观看| .国产精品久久| 一级毛片我不卡| 国产亚洲精品久久久久久毛片| 午夜老司机福利剧场| 成人特级黄色片久久久久久久| 亚洲四区av| 亚洲成人久久性| 亚洲人与动物交配视频| 亚洲成人精品中文字幕电影| 又爽又黄无遮挡网站| 欧美日韩精品成人综合77777| 美女高潮的动态| 国产午夜福利久久久久久| 你懂的网址亚洲精品在线观看 | 秋霞在线观看毛片| 亚洲欧美日韩东京热| 深夜精品福利| 国产视频内射| 在线天堂最新版资源| 美女xxoo啪啪120秒动态图| 亚洲av成人精品一区久久| 亚洲精品成人久久久久久| 国产黄色视频一区二区在线观看 | 亚洲欧美中文字幕日韩二区| 欧美最新免费一区二区三区| 搡老妇女老女人老熟妇| 亚洲丝袜综合中文字幕| 久久精品夜夜夜夜夜久久蜜豆| 最近2019中文字幕mv第一页| 在线天堂最新版资源| 亚洲av第一区精品v没综合| 看黄色毛片网站| 欧美精品国产亚洲| 亚洲av中文字字幕乱码综合| 日韩成人av中文字幕在线观看 | 久久九九热精品免费| 12—13女人毛片做爰片一| 午夜爱爱视频在线播放| 国产精品无大码| 中文字幕免费在线视频6| 香蕉av资源在线| 精品久久久久久久久久免费视频| 久久精品综合一区二区三区| 久久久久久久久久成人| 六月丁香七月| 全区人妻精品视频| 麻豆成人午夜福利视频| 神马国产精品三级电影在线观看| 欧美3d第一页| 91午夜精品亚洲一区二区三区| 国产亚洲av嫩草精品影院| 黄色一级大片看看| 观看美女的网站| 国产精品电影一区二区三区| 国产成年人精品一区二区| 国产精品永久免费网站| 一区福利在线观看| 国产69精品久久久久777片| 天天躁夜夜躁狠狠久久av| 亚洲最大成人手机在线| 国产精品亚洲一级av第二区| 搡老妇女老女人老熟妇| 国产伦一二天堂av在线观看| 中文字幕熟女人妻在线| 成人欧美大片| 亚洲精品粉嫩美女一区| 中文在线观看免费www的网站| 欧美bdsm另类| 国产麻豆成人av免费视频| 我的老师免费观看完整版| 欧美xxxx黑人xx丫x性爽| 看免费成人av毛片| 九九热线精品视视频播放| 观看免费一级毛片| www.色视频.com| 久久久国产成人精品二区| 亚洲av中文av极速乱| 日韩亚洲欧美综合| 成人亚洲欧美一区二区av| 亚洲av第一区精品v没综合| 蜜桃久久精品国产亚洲av| 亚洲国产精品sss在线观看| 高清毛片免费看| 亚洲av成人av| 18+在线观看网站| 99九九线精品视频在线观看视频| 黄色日韩在线| 99在线视频只有这里精品首页| 亚洲精品在线观看二区| 精品久久久久久成人av| 国产精品人妻久久久影院| 18+在线观看网站| 日日干狠狠操夜夜爽| 夜夜看夜夜爽夜夜摸| 国产中年淑女户外野战色| 18禁黄网站禁片免费观看直播| 中文在线观看免费www的网站| 少妇的逼好多水| 内射极品少妇av片p| 18禁裸乳无遮挡免费网站照片| 一进一出抽搐gif免费好疼| 欧美中文日本在线观看视频| 国产精品,欧美在线| 日韩一区二区视频免费看| 亚洲七黄色美女视频| 精品熟女少妇av免费看| aaaaa片日本免费| 国产伦精品一区二区三区视频9| 天堂网av新在线| 免费大片18禁| 国产精品亚洲一级av第二区| 国产麻豆成人av免费视频| 国产不卡一卡二| 国产在线精品亚洲第一网站| 乱人视频在线观看| 亚洲精品一卡2卡三卡4卡5卡| 能在线免费观看的黄片| 日韩欧美精品v在线| 高清毛片免费看| 男女边吃奶边做爰视频| 久久久久国产精品人妻aⅴ院| 日本欧美国产在线视频| 亚洲美女黄片视频| 十八禁国产超污无遮挡网站| 久久综合国产亚洲精品| 欧美区成人在线视频| 免费在线观看成人毛片| 国产伦精品一区二区三区视频9| 日韩一区二区视频免费看| 日本爱情动作片www.在线观看 | 国产亚洲精品久久久com| 亚洲av中文av极速乱| 亚洲不卡免费看| АⅤ资源中文在线天堂| 久久久久久久久久成人| 亚洲va在线va天堂va国产| 波多野结衣高清无吗| 国产91av在线免费观看| 免费高清视频大片| 国产成人freesex在线 | 国产 一区精品| 老女人水多毛片| 偷拍熟女少妇极品色| 久久久久国产网址| 人妻少妇偷人精品九色| 国产一区二区在线观看日韩| 成人欧美大片| 毛片一级片免费看久久久久| 22中文网久久字幕| 欧美另类亚洲清纯唯美| 97在线视频观看| 亚洲av五月六月丁香网| 午夜激情欧美在线| 久久久久久伊人网av| 久久久欧美国产精品| 亚洲精品久久国产高清桃花| 自拍偷自拍亚洲精品老妇| 日韩欧美国产在线观看| 欧美一区二区亚洲| 不卡一级毛片| 国产精品久久久久久久久免| 床上黄色一级片| 三级经典国产精品| 狂野欧美白嫩少妇大欣赏| 99久久精品热视频| 中文资源天堂在线| 久久午夜福利片| 2021天堂中文幕一二区在线观| 最近最新中文字幕大全电影3| 99久久中文字幕三级久久日本| 亚洲在线自拍视频| 国产精品爽爽va在线观看网站| 国产伦在线观看视频一区| 一个人观看的视频www高清免费观看| h日本视频在线播放| 99riav亚洲国产免费| 我的老师免费观看完整版| 精品人妻熟女av久视频| 亚洲精品一区av在线观看| 久久草成人影院| 日韩制服骚丝袜av| 日韩欧美国产在线观看| 99九九线精品视频在线观看视频| 日本-黄色视频高清免费观看| 晚上一个人看的免费电影| 日韩制服骚丝袜av| 99热精品在线国产| av视频在线观看入口| 成人毛片a级毛片在线播放| 别揉我奶头 嗯啊视频| 成人漫画全彩无遮挡| 久久精品91蜜桃| 成熟少妇高潮喷水视频| 淫秽高清视频在线观看| 九九在线视频观看精品| 国产精品久久久久久久久免| 国产一区二区亚洲精品在线观看| 国产精品1区2区在线观看.| 亚洲成a人片在线一区二区| 日本精品一区二区三区蜜桃| 日韩国内少妇激情av| 亚洲成人久久爱视频| 国产精品一及| 国产精品99久久久久久久久| 精品一区二区三区视频在线| 菩萨蛮人人尽说江南好唐韦庄 | 夜夜夜夜夜久久久久| 精品午夜福利在线看| 亚洲色图av天堂| 久久精品夜色国产| 亚州av有码| 看十八女毛片水多多多| 久久精品国产亚洲网站| 十八禁网站免费在线| 欧美最新免费一区二区三区| 97超级碰碰碰精品色视频在线观看| 欧美精品国产亚洲| 亚洲专区国产一区二区| 国产精品伦人一区二区| 麻豆国产97在线/欧美| 国产熟女欧美一区二区| 国产精品久久久久久久久免| 女生性感内裤真人,穿戴方法视频| 熟女电影av网|